Core Viewpoint - Genenta Science S.p.A. is transitioning to Saentra Forge, focusing on strategic industrial consolidation in biotech, defense, aerospace, and Italian national-security-related technologies [1] Company Developments - Pierluigi Paracchi, CEO of the company, has been appointed to the Board of Guarantors of the Italian Academy for Advanced Studies in America, enhancing the company's connection to cultural and academic institutions [1][2] - The Board of Guarantors consists of twelve members, with six appointed by the Italian Government and six by Columbia University, playing a crucial role in supporting the Academy's activities [2][3] Strategic Focus - Saentra Forge aims to consolidate specialized companies in sectors regulated by Italian national security, including cybersecurity, defense, aerospace, and biotechnology/biosecurity [4] - The company emphasizes the importance of connecting science, industry, and international collaboration for long-term competitiveness, aligning with the Academy's mission [4]

Core Insights - Genenta Science S.p.A. is transitioning to Saentra Forge, focusing on strategic industrial consolidation in biotech, defense, aerospace, and Italian national-security-related technologies [1][4] - Pierluigi Paracchi, CEO of the company, has been appointed to the Board of Guarantors of the Italian Academy for Advanced Studies in America, enhancing the company's ties with academic institutions [2][4] Company Overview - Genenta Science, soon to be known as Saentra Forge, will operate as a next-generation strategic consolidator targeting privately held specialized companies in sectors regulated by Italian national security, including cybersecurity, defense, aerospace, and biotechnology/biosecurity [1][4] Board of Guarantors - The Board of Guarantors consists of twelve members, with six appointed by the Italian Government and six by Columbia University, playing a crucial role in supporting the Academy's activities and maintaining academic excellence [2][3] - The Italian Academy for Advanced Studies in America, founded in 1991, promotes dialogue and collaboration among scholars and artists, fostering Italian culture and intellectual exchange [3]

Core Insights - Genenta Science S.p.A. is transitioning to Saentra Forge, focusing on biotech, defense, aerospace, and national-security technologies [1] - The company appointed Paolo Salvato to the Board of Directors of ATC, marking its entry into defense technology manufacturing [1] - Genenta is evaluating acquisition opportunities in regulated national-security sectors to build a strategic industrial consolidator [3] Company Developments - Paolo Salvato has over two decades of experience in defense industrial operations, previously serving as CEO of Fiocchi Munizioni and Thales Italia [2] - The company aims to acquire profitable, majority-controlled, privately-held industrial businesses, leveraging its Nasdaq listing for financial flexibility [4][6] - Genenta's biotech program has reached clinical maturity, with a focus on strategic partnerships to advance development and minimize risk [6] Clinical and Scientific Progress - Nature Medicine has accepted a manuscript detailing clinical findings from Genenta's Glioblastoma Multiforme trial, expected to be published soon [5] - The publication is seen as a validation of the company's scientific and clinical efforts [5] Strategic Vision - The transformation reflects a response to evolving market dynamics, with an emphasis on the intersection of advanced biotechnology and defense technologies [6] - The company is focused on acquiring businesses with positive EBITDA and integrating them into a transparent, publicly listed platform for long-term value creation [6]

Core Viewpoint - Genenta Science S.p.A is transforming into Saentra Forge S.p.A, focusing on acquiring privately held businesses in national-security regulated sectors under Italian Golden Power legislation, targeting companies with up to €5 million in EBITDA [1][10] Group 1: Strategic Transformation - The company aims to become a next-generation strategic industrial consolidator, pursuing a value-creation strategy by acquiring targets at private-market valuations and integrating them under Saentra Forge [2] - The first acquisition target is ATC, a defense-sector company specializing in high-precision manufacturing of tactical rifles and special-forces weapon systems [3] Group 2: Financial Projections and Funding - Genenta plans to fund ATC with a total of €5.1 million through performance-driven tranches, aiming for a controlling position upon achieving defined performance milestones [3] - ATC projects revenues of approximately €4.0 million in 2026, increasing to around €9.0 million by 2027, with an expected EBITDA of more than €2.0 million in 2026, potentially doubling in 2027 [3] Group 3: Governance and Strategic Partnerships - The Praexidia Foundation has joined as a strategic long-term shareholder, enhancing the company's governance framework and supporting regulatory coherence [4][5] - A shareholders' agreement has been established to ensure consultation rights on significant corporate transactions and a renewable five-year lock-up, reinforcing long-term alignment and effective control [5] Group 4: Biotech and Cash Position - The company has reached key clinical milestones in its cell therapy platform, engaging DC Advisory as its exclusive financial advisor for partnership initiatives [6] - Expected cash, cash equivalents, and marketable securities at December 31, 2025, are approximately $33 million, up from $17.7 million at June 30, 2025, primarily due to a registered direct offering [9]

Core Viewpoint - Genenta Science provides an update on the ownership position of its CEO and Co-Founder, Pierluigi Paracchi, highlighting his significant investment in the company through open-market purchases of American Depositary Shares (ADSs) [1][2]. Company Ownership - Pierluigi Paracchi has acquired a total of 30,000 ADSs through open-market purchases, with no reported sales [2]. - As of December 19, 2025, Mr. Paracchi owns 2,326,129 ADSs and ordinary shares, representing approximately 10% of Genenta's outstanding share capital [3]. Company Overview - Genenta Science is a clinical-stage immuno-oncology company focused on developing hematopoietic stem cell therapies for solid tumor cancers [4]. - The company's lead product candidate, Temferon™, aims to express immune-therapeutic payloads within the tumor microenvironment, potentially enhancing immune responses [4]. - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients, indicating potential for reprogramming the tumor microenvironment and inducing T cell responses [4]. - A Phase 1/2a study for metastatic Renal Cell Carcinoma has been initiated, which will explore combinations with immune checkpoint inhibitors [4]. - Genenta's therapies are designed as one-time monotherapies but may also enhance the efficacy of other approved treatments when used in combination [4].

Core Insights - Genenta Science has provided an update on its TEM-GBM study for newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT gene promoter, reporting that 25 patients have been treated with Temferon as of November 21, 2025 [1][2] Group 1: Clinical Study Results - Key survival metrics for TEM-GBM patients show that 44% of patients have reached 18-month survival, an increase from 38% reported in April 2025 [7] - The two-year survival rate remains at 29%, and the median overall survival is consistent at 17 months, compared to historical cohorts of uMGMT patients treated with standard care, which typically show a two-year survival rate of approximately 14% and median overall survival of 13-15 months [7] - The study includes a patient who has reached three years of survival following Temferon administration, marking a significant milestone in the study [7] Group 2: Mechanism and Observations - The GBM study provides early observations on Temferon's behavior within the tumor microenvironment, indicating that bone-marrow-derived myeloid cells can deliver immunotherapeutic payloads at the tumor site, aligning with the platform's intended design [3] - These preliminary findings are exploratory and will inform the broader development of Temferon, including potential combination approaches and the evolution of the underlying cell-based delivery technology [3] Group 3: Financial Position - Following a registered direct offering on October 27, the company reported approximately $30 million in cash and short-term investments as of November 1, 2025 [4] Group 4: Company Overview - Genenta Science is a clinical-stage immuno-oncology company developing a proprietary hematopoietic stem cell therapy for various solid tumor cancers, with Temferon as its first-in-class product candidate [5] - The company has completed a Phase 1 trial for newly diagnosed GBM patients with an unmethylated MGMT gene promoter, suggesting potential reprogramming of the tumor microenvironment and induction of T cell responses [5] - Genenta has also initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will include combinations with immune checkpoint inhibitors [5]

Core Viewpoint - Genenta Science has entered into a securities purchase agreement to sell 4,285,715 American Depositary Shares (ADSs) at $3.50 per ADS, aiming for gross proceeds of approximately $15.0 million before expenses [1][2]. Group 1: Offering Details - The offering involves the sale of securities solely by Genenta, with no warrants or derivative securities issued [1]. - Maxim Group LLC is the lead placement agent, while Rodman & Renshaw LLC acts as the co-placement agent for the offering [2]. - The expected closing date for the offering is around October 28, 2025, pending customary closing conditions [2]. Group 2: Use of Proceeds - Genenta plans to utilize the net proceeds from the offering for working capital and general corporate purposes [2]. Group 3: Company Overview - Genenta Science is a clinical-stage immuno-oncology company focused on developing proprietary hematopoietic stem cell therapies for solid tumor cancers [5]. - The company's lead product candidate, Temferon™, aims to express immune-therapeutic payloads within the tumor microenvironment, potentially enhancing immune responses [5]. - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients and has initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will include combinations with immune checkpoint inhibitors [5].

Core Insights - Genenta Science and ANEMOCYTE have announced a strategic collaboration focusing on off-the-shelf lentiviral vector (LVV) Plasmid DNA technology, expanding their existing partnership in plasmid DNA production [1][2][3] - The collaboration aims to enhance ANEMOCYTE's offerings by utilizing Genenta's established LVV Plasmid DNA technology, which is based on foundational research by Professor Luigi Naldini [2][3] - This partnership is expected to support the development of advanced therapy programs across the life sciences industry, ensuring clients have access to reliable and scalable solutions [3] Company Overview - Genenta Science is a clinical-stage immuno-oncology company developing a proprietary hematopoietic stem cell therapy for solid tumor cancers, with its lead product candidate being Temferon™ [5] - Temferon™ is designed to express immune-therapeutic payloads within the tumor microenvironment, potentially enhancing T cell responses and breaking immune tolerance [5] - ANEMOCYTE is a Biotech Manufacturing Organization based in Italy, specializing in the development and manufacturing of pDNA and mRNA, with over 25 years of expertise in innovative therapies [4]

Core Insights - Genenta Science and ANEMOCYTE have announced a strategic collaboration focusing on off-the-shelf lentiviral vector (LVV) Plasmid DNA technology, expanding their existing partnership in plasmid DNA production [1][3] - The collaboration aims to leverage Genenta's established LVV Plasmid DNA technology, enhancing ANEMOCYTE's offerings to clients by providing high-quality materials from R&D to GMP grade [2][3] - This partnership signifies a commitment to supporting the life science industry with innovative solutions, ensuring clients have access to a reliable platform for advanced therapy programs [3] Company Profiles - Genenta Science is a clinical-stage immuno-oncology company developing a proprietary hematopoietic stem cell therapy for various solid tumor cancers, with its first-in-class product candidate, Temferon™, designed to express immune-therapeutic payloads within the tumor microenvironment [5] - ANEMOCYTE is a Biotech Manufacturing Organization based in Italy, specializing in the development and manufacturing of pDNA and mRNA, with over 25 years of expertise in innovative therapies [4]

Core Insights - Genenta Science is conducting ongoing clinical trials for its immuno-oncology product, Temferon, focusing on glioblastoma multiforme and genitourinary tumors [1][3][6] Group 1: Glioblastoma Multiforme Study - A total of 38 patients have been enrolled in the glioblastoma multiforme study, with 25 patients receiving Temferon [1] - The two-year survival rate for unmethylated MGMT (uMGMT) patients in the GBM trial is 29%, with a median overall survival of 17 months, compared to historical cohorts showing a 14% survival rate and a median overall survival of 13 to 15 months [2] - Two patients have been enrolled in a long-term follow-up study, with one showing no disease progression and the other stabilizing after initial progression, indicating potential efficacy of Temferon [1] Group 2: Genitourinary Tumor Study - The TEM-GU Phase 1 study has begun recruitment, aiming to enroll 12 patients with genitourinary tumors, administering Temferon at a fixed dose of 4 million genetically modified cells per kilogram [3] - The study will evaluate the safety and tolerability of Temferon in combination with immune checkpoint inhibitors or tyrosine kinase inhibitors [3] Group 3: Mechanism of Action - Temferon works by reprogramming the tumor microenvironment to enhance adaptive immune responses [4] - A scientific manuscript has been accepted for publication, demonstrating Temferon's potential to enhance CAR-T activity in preclinical models [4][5] Group 4: Company Overview - Genenta Science is a clinical-stage immuno-oncology company developing hematopoietic stem cell therapy for solid tumors, with Temferon as its first product candidate [6] - The company has completed a Phase 1 trial for newly diagnosed GBM patients with an unmethylated MGMT gene promoter, suggesting potential for reprogramming the tumor microenvironment [6]